KD Logo

Director SCHULMAN AMY W sold 8,500 shares of Alnylam Pharmaceuticals Inc [ALNY]

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Alnylam Pharmaceuticals Inc shares valued at $2,040,000 were sold by SCHULMAN AMY W on Jun 25 ’24. At $240.00 per share, SCHULMAN AMY W sold 8,500 shares. The insider’s holdings dropped to 8,436 shares worth approximately $2.1 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Also, Greenstreet Yvonne sold 8,301 shares, netting a total of over 1,917,475 in proceeds. Following the sale of shares at $230.99 each, the insider now holds 80,534 shares.

Before that, Garg Pushkal had sold 2,103 shares from its account. In a trade valued at $485,773, the CMO & EVP Dev & Med Affairs traded Alnylam Pharmaceuticals Inc shares for $230.99 each. Upon closing the transaction, the insider’s holdings decreased to 2,103 shares, worth approximately $3.88 million.

As published in a research note from Goldman on February 16, 2024, Alnylam Pharmaceuticals Inc [ALNY] has been rated down from a Buy to a Neutral and the price target has been revised to $173. Analysts at Wolfe Research started covering the stock with ‘”a Peer perform”‘ outlook in a report released in mid February. As of December 08, 2023, Wells Fargo has initiated its “an Equal weight” rating for ALNY. Earlier on December 08, 2023, Wells Fargo initiated its rating. Their recommendation was “an Equal weight” for ALNY stock.

Analyzing ALNY Stock Performance

During the last five days, there has been a surge of approximately 1.50%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 30.00%. Shares of the company reached a 52-week high of $252.87 on 06/27/24 and a 52-week low of $141.98 on 04/25/24. A 50-day SMA is recorded $165.71, while a 200-day SMA reached $166.71. Nevertheless, trading volume fell to 0.95 million shares from 1.58 million shares the previous day.

Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)

According to the 24-hour chart, there is a support level at 246.22, which, if violated, would cause prices to drop to 243.75. In the upper region, resistance lies at 250.41. The next price resistance is at 252.13. RSI (Relative Strength Index) is 87.62 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 39.93, which suggests the price will increase in the coming days. Percent R is at 4.17%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Most Popular